By MyWay

Translated by Mount Royal Montreal Group夏星湖

Coronavirus disease (COVID-19) is a new form of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although most patients with SARS-CoV-2 infection present asymptomatic or with only mild or moderate symptoms, approximately 15-20% of them will develop severe pneumonia, and approximately 5% of patients will develop acute respiratory distress syndrome (ARDS). The main causes of death from SARS-COVID-2 is respiratory failure, infectious shock, heart failure, hemorrhage, and renal failure. The pathogenic mechanism of the virus is mainly by stimulating the body to produce an inflammatory cytokine storm response (ICSR), which leads to an inflammatory response in the body. This uncontrolled inflammatory response will lead to infectious shock, multi-organ damage, and eventual organ failure. Once the virus enters the body, it immediately undergoes rapid replication. A single viral particle entering a cell is capable of producing approximately one million new viral particles. The viral spike protein binds not only to the ACE2 receptor but also to other receptors. These receptors are dependent on the sialic acid CD147 receptor and are known as the a7nAChr cholinergic receptor. The specific viral pathogenesis is not described here.

Once the virus gets in the lungs and causes damage, the virus enters the bloodstream and attaches itself to red blood cells and platelets. Because both are surrounded by sialic acid and CD147 receptors, the virus invades all blood vessels and “released” into the lining of the blood vessels which lead to systemic vasculitis. This is why most of the victims eventually fail to overcome the infection. The mechanism by which the virus moves through the bloodstream also explains why the virus is more lethal in hyperglycemic patients, such as diabetics and prediabetics. This is because the receptors consisting of sialic acid and CD147 are essentially sugar. In diabetic patients, because salivary acid is richer in sugar (glucose) the virus adheres better and its systemic transmission is even easier. The selectivity of the virus for its target also occurs with respect to blood type. For example, those with blood type A or B have more sialic acid/sugar present on the surface of their red blood cells. Blood type O, on the other hand, is less susceptible to the virus because it has fewer sialic acid receptors in the red blood cells and less retention of the virus. Patients with diabetes or those with blood types A and B will have statistically more severe diseases.

When the virus replicates within the vascular endothelium, it inflames it and forms sticky aggregates of red blood cells and platelets. The small clots that initially obstruct the blood vessels cause localized circulation in the capillaries, which then gradually swell and block larger and larger vessels. When this happens in the lungs, it leads to a lack of oxygen. This damages all of our organs such as the brain, liver, kidneys and heart. This is especially fatal for the elderly, diabetics and people with undying diseases.

As a result of past in vitro experiments and clinical experience, the following drugs that have proven to be clinically effective in the prevention and treatment of COVID-19:

Hydroxychloroquine: Hydroxychloroquine is a very safe drug. It has a superb ability to reach far, even in prophylactic doses. It has superb ability to reach cells in all tissues and organs of the body and is 200 to 700 times more concentrated in the lungs than in other parts of the body. Hydroxychloroquine inhibits viral RNA replication and repackaging by reducing the ambient acidity of key structural endocytoplasms such as the endoplasmic reticulum and Golgi apparatus, interfering with viral glycosylation, and inhibiting the ability of viral S proteins to embed in ACE2 receptors. Hydroxychloroquine has a very high safety profile. Billions of doses have been used worldwide in the last decades. And for prophylaxis only only very low doses are needed, thus eliminating the negative effects of possible side effects on the body.

Ivermectin: Ivermectin is an antiparasitic drug approved by the U.S. Food and Drug Administration (FDA). It is used to treat several neglected tropical diseases, including onchocerciasis, and mixed intestinal helminthiasis. Since viruses tend to enhance infection by inhibiting the host antiviral response, SARS-CoV-2 also hijacks the host importin alpha/beta-1 nuclear transporter protein. Ivermectin inhibits the host importin α/β-1 nuclear transporter protein, which is the basis of ivermectin’s broad-spectrum in vitro activity against dengue, Zika, HIV, and yellow fever viruses.

The potent antiviral and anti-inflammatory effects of ivermectin on COVID-19 have been demonstrated in both laboratory and clinical trial studies. More than 40 clinical studies around the world have shown that ivermectin is not only extremely effective in reducing viremia in the early stages of infection, but also remains effective in the secondary phase. In one study in Argentina, none of the 788 healthcare professionals who took 12 mg of ivermectin once a week became infected. And hospitalization or further exacerbation was prevented by the use of this drug in patients infected with Covid. Ivermectin has more than one mechanism of action that may be effective against Covid-19. One of the main mechanisms is its ability to bind to the coronavirus Spike-1 protein, thus preventing the virus from attaching to ACE2. This in turn reduces the ability of the virus to enter the body. Thus ivermectin can fight all coronavirus variants. Ivermectin creates a barrier between the patient’s body (red blood cells, platelets and blood vessels) and the virus, thus facilitating the flow of oxygen-carrying red blood cells in the blood vessels. Patients can miraculously begin to breathe normally and the function of all organs improves rapidly. Another reason why ivermectin is effective at different stages of viral infection is that it has not only antiviral but also antiplatelet effects (similar to those of heparin and aspirin but more specific). In addition, ivermectin has a powerful anti-inflammatory effect similar to that of cortisone but is not immunosuppressive like cortisone. Thus, during administration, the immune response of T and B cells (which produce antibodies) continues to function and suppresses the production of cytokine storms.

Vitamin C: It improves cellular immune response and affects phagocytosis, the transformation of T-lymphocytes, and the production of interferon. In vitro experiments have shown that vitamin C can increase the resistance of chicken embryo organ cultures and prevent viral infections.

Zinc: Zinc effectively prevents RNA-dependent RNA polymerase (RDRP) from contacting ribosomes, thereby inhibiting viral replication.

Vitamin D: Vitamin D deficiency has been clinically shown to lead to increased complications following viral infections, so increasing vitamin D levels in the body is also useful in fighting viral infections.

Azithromycin: The mechanism of action prevents bacterial growth by interfering with bacterial protein synthesis, which binds to the 50S subunit of the bacterial ribosome, thereby inhibiting the translation of mRNA. The mechanism of action for azithromycin’s enhanced efficacy against viral infections is not well understood, but azithromycin has previously been shown to inhibit both Sika and Ebola viruses in vitro and to prevent severe respiratory infections when administered to patients with viral infections.

Quercetin: is a naturally occurring dietary flavonoid. It may improve chronic diseases and the aging process in humans. Its antiviral properties have been investigated in numerous studies. In vitro studies have shown that quercetin can interfere with various stages of the coronavirus entry and replication cycle. There is evidence that quercetin, in combination with vitamins C and D, may exert synergistic antiviral effects due to overlapping antiviral and immunomodulatory properties, which may provide alternative or additional therapeutic/preventive options.

The following prevention and treatment protocols are recommended by Vladimir Zelenko.

Prevention regimen (low to moderate risk population):
Elemental zinc 25mg once daily
Vitamin D 5000iu once a day
Vitamin C 1000mg once a day
Quercetin 500mg once daily until a safe and effective vaccine is available
If quercetin is not available, green tea (EGCG) 400mg once daily

Prevention program (high-risk groups) :
Elemental zinc 25mg once a day
Vitamin D 5000iu once a day
Vitamin C 1000mg once a day
Hydroxychloroquine sulfate 200mg per day for 5 days, then 200mg per week
If hydroxychloroquine is not available, please refer to the prevention program for low and medium risk groups

Treatment regimen (low to moderate risk patients) :
Quercetin 500mg morning and evening for 7 days
Vitamin C 1000mg daily for 7 days
Elemental zinc 25mg daily for 7 days
Rest, liquid diet, and doctor’s follow-up

Treatment regimen (high-risk patients) :
Hydroxychloroquine 200mg in the morning and 200mg in the evening for 5-7 days
or Quercetin 500mg morning, noon, and night for 5-7 days
or Chlorophyllin 400mg in the morning and 400mg in the evening for 5-7 days
Azithromycin 500mg daily for 5 days
Or Doxycycline 100mg morning and evening for 5-7 days
Elemental zinc 50mg daily for 7 days
Rest, liquid diet, and doctor’s follow-up

Alternative regimen:
Ivermectin 6mg in the morning and 6mg in the evening
Budesonide 1mg/2mL morning and evening nebulized inhalation for 7 days
Dexamethasone 6mg daily for 5 days
Blood thinners (e.g. Lovenox)
Oxygen inhalation
Intravenous rehydration

In addition, there are ivermectin-led prophylactic and therapeutic regimens recommended by the FLCCC.

Prophylaxis regimen (high-risk population) :
Ivermectin 0.2 mg/kg body weight with a meal, repeated once after 48 hours and weekly thereafter (daily prophylaxis)
Ivermectin 0.2mg/kg body weight with a meal, repeated once after 48 hours (after exposure to the risk of infection)
Elemental zinc 30-40mg once daily
Vitamin D 1000-3000iu once daily
Vitamin C 500-1000mg twice daily
Quercetin 250mg once daily
Melatonin 6mg daily at bedtime

Early treatment regimen (low to moderate risk patients) :
Ivermectin 0.2-0.4mg/kg body weight with a meal once daily until the body recovers
Fluvoxamine 50mg twice daily for 1-14 days (only in combination with ivermectin under limited conditions)
Vitamin D 4000iu once a day
Vitamin C 500-1000mg twice daily
Quercetin 250mg once in the morning and once in the evening
Elemental zinc 100mg daily
Melatonin 10mg daily before bedtime
Aspirin 325mg daily

Note: The above prevention and treatment protocols are for readers’ reference only, please consult your physician for personalized medical advice.

Reference link:

【1】Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”
【2】COVID-19发病机制的免疫特征
【3】槲皮素:抗病毒意义和可能的COVID-19综合考虑
【4】美国NIH更新了关于伊维菌素治疗COVID-19的进展
【5】I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
【6】Safe&Prosper protocol
【7】Zelenko Protocols against Covid-19

Original article: https://gnews.org/post/p1327734/